Alligator Bioscience has appointed Gayle Mills as Chief Business Officer to lead the company’s Business Development activities.
Mills will be a member of the executive management team at Alligator Bioscience.
Executing large R&D collaborations and transactions
Gayle Mills is a renowned business development professional with an unmatched industry network and an extensive knowledge of the biotech and pharma landscape, states the company. She has a successful track record of executing large R&D collaborations and transactions and has held senior positions with Roche Bioscience, Abgenix, Inc. and Symphogen A/S. She joined Alligator Bioscience on September 28, 2020.
“With Gayle’s background and deep understanding of the antibody drug development process, and her proven track record of signing deals, it is with great excitement I welcome Gayle to Alligator and to my executive management team,” says Per Norlén, CEO at Alligator Bioscience.